Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 3, 2012, Pages 378-386

  Bracarda, Sergio ^a   Ruggeri, Enzo Maria ^b   Monti, Marcello ^c   Merlano, Marco ^d   D'Angelo, Alessandro ^e   Ferraù, Francesco ^e   Cortesi, Enrico ^f   Santoro, Armando ^g  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b BELCOLLE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e Ospedale Civico San Vincenzo   (Italy)

^f POLICLINICO UMBERTO I   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Cutaneous adverse events; Guidelines; Hand foot skin reaction; Prevention; Sorafenib; Targeted therapy

Indexed keywords

ANTIHISTAMINIC AGENT; CAPECITABINE; CHLORIDE; CYTARABINE; DOXORUBICIN; EMOLLIENT AGENT; FLUOROURACIL; MAGNESIUM SILICATE; SORAFENIB; SULFOSALICYLIC ACID; ZINC OXIDE;

ANTIPROLIFERATIVE ACTIVITY; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRY SKIN; EARLY DIAGNOSIS; ERYTHEMA; FATIGUE; FOLLICULAR RASH; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KERATINOCYTE; KERATOACANTHOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG DISEASE; NAUSEA; PAIN; PRIMARY PREVENTION; PRURITUS; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; DISEASE MANAGEMENT; EXANTHEMA; HUMANS; KERATOACANTHOMA; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PRURITUS; PYRIDINES; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84861191918     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.08.005     Document Type: Review

References (35)

1. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
2. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
3. Di Lorenzo G., Porta C., Bellmunt J., et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011, January 14 [Epub ahead of print].
4. Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int 2011, January 20 [Epub ahead of print]. 10.1111/j.1464-410X.2010.09985.x.
5. Porta C., Paglino C., Imarisio I., et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007, 7(December (4)):127-134.
6. Chu D., Lacouture M.E., Fillos T., Shenhong W.U. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008, 47:176-186.
7. Bellmunt J., Eisen T., Fishman M., Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011, 78:24-32.
8. Monti M., Motta S. Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers 2007, 22(1 (Suppl. 4)):S53-S61.
9. Bracarda S., Caserta C., Sordini L., et al. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 2007, 18(June (Suppl. 6)):vi22-vi25.
10. Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(October (10)):3129-3140.
11. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). N Engl J Med 2008, 359:378-390.
12. Hutson T.E., Bellmunt J., Porta C., et al. Long-term safety with sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010, 46:2432-2440.
13. Naito S., Tsukamoto T., Murai M., Fukino K., Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int 2011 April, 10.1111/j.1464-410X.2011.10281.x.
14. Strumberg D., Clark J.W., Awada A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12:426-437.
15. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
16. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
17. Hartmann J.T., Haap M., Kopp H.G., Lipp H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009, 10(June (5)):470-481.
18. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(January (1)):25-34.
19. Lacouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand-foot reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001-1011.
20. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6(July (7)):491-500.
21. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(July (20)):3312-3318.
22. Lipworth A.D., Robert C., Zhu A.X. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009, 77(5). 257-271.99.
23. Yang C.H., Lin W.C., Chuang C.K., et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008, 158:592-596.
24. Pastore S., Mascia F., Mariotti F., Dattilo C., Mariani V., Girolomoni G. Expression and skin inflammation ERK1/2 regulates epidermal chemokine and skin inflammation. J Immunol 2005, 174:5047-5056.
25. Autier J., Escudier B., Wechsler J., Spatz A., Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008, 144(7):886-892.
26. Cirillo N., Prime S.S. Desmosomal interactome in keratinocytes: a systems biology approach leading to an understanding of the pathogenesis of skin disease. Cell Mol Life Sci 2009, 66:3517-3533.
27. Arnault J.P., Wechsler J., Escudier B., et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009, 27(August (23)):e59-e61.
28. Kong H.H., Cowen E.W., Azad N.S., et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007, 56(January (1)):171-172.
29. Jantzem H., Dupre-Goetghebeur D., Spindler P., Merrer J. Sorafenib-induced multiple eruptive keratoacanthomas. Ann Dermatol Venereol 2009, 136(December (12)):894-897.
30. Eisen T., Oudard S., Szczylik C., et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008, 100(October (20)):1454-1463.
31. Bukowski R.M., Stadler W.M., McDermott D.F., et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010, 78(5-6):340-347.
32. Beck J., Procopio G., Bajetta E., et al. Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011, February 15 [Epub ahead of print].
33. Di Maio M., Gridelli C., Gallo C., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005, 6(September (9)):669-677.
34. Vincenzi B., Santini D., Russo A., et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010, 15:85-92.
35. Cobo M., Cardenal F., Insa A., et al. Skin as a surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib. J Clin Oncol 2007, 7602. (ASCO Annual Meeting Proceedings Part I, vol. 25, No. 18s).